Furthermore, statistical analysis revealed a highly significant difference in prediction scores before and after mutation ( P < 1.1 × 10 −13 ), indicating that mutations significantly affected prediction scores in most samples, with the observed reductions strongly correlated with alterations at the CDR3–epitope binding interface.
As presented in Figure 6 a , both functional biomarkers, INAL ( P = 0.059) and RTCF ( P = 0.097), showed a strong trend towards higher levels in the responder group (CR/PR; n = 7) compared to non‐responders (SD/PD; n = 21).
While the trend for functional biomarkers did not reach statistical significance, likely due to the limited sample size of the responder cohort, it pointed towards their superior relevance to therapeutic benefit.